Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Unknown 2Terminated 2

Sponsor Class

OTHER 2NIH 2

Study Type

Observational 11Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Rectal Neoplasms 13Breast Neoplasms 12Colorectal Neoplasms 11Colonic Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia 9Carcinoma, Non-Small-Cell Lung 9Leukemia, Myeloid, Acute 8Carcinoma, Renal Cell 8Prostatic Neoplasms 7Lung Neoplasms 7Kidney Neoplasms 7Multiple Myeloma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Gliosarcoma 6Glioblastoma 6Esophageal Neoplasms 6Congenital Abnormalities 6Stomach Neoplasms 5Melanoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Myelodysplastic Syndromes 4Lymphoma, Large-Cell, Immunoblastic 4

Interventions

Cyclophosphamide 444Rituximab 401Etoposide 224Vincristine 215Doxorubicin 201Filgrastim 200Prednisone 176Cytarabine 159Radiotherapy 152fludarabine phosphate 147Methotrexate 137Peripheral Blood Stem Cell Transplantation 129Melphalan 127fludarabine 115Busulfan 99Dexamethasone 93Tacrolimus 75Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 71Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 62Cyclosporine 62Bendamustine Hydrochloride 62Lenalidomide 60Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Lymphoma × Gene Expression Profiling × Clear all
NCT00691652 2019-11-27

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

OHSU Knight Cancer Institute

Phase 1/2 Terminated
2 enrolled 4 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00851552 2014-07-21

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Roswell Park Cancer Institute

Phase 2 Terminated
9 enrolled 5 charts
Lymphoid

Lymphoma, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

NCT00893477 2013-08-02

GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 2 Unknown
60 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT00896519 2013-08-02

GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡